文献速递中毒与环境急症消化、代谢与肾脏急症

美国疑似环肽蕈类中毒当前病死率

Current fatality rate of suspected cyclopeptide mushroom poisoning in the United States.
PubMed 文献 · Clin Toxicol (Phila) · 2020-04-02
一句话结论美国国家毒物数据系统11年回顾性分析显示,疑似含环肽蕈类摄入并符合特定纳入标准者总病死率为8.8%(13/148),水飞蓟宾/水飞蓟素治疗组与未治疗组病死率无显著差异。

本研究为2008年1月1日至2018年12月31日对美国国家毒物数据系统(NPDS)报告的疑似含环肽蕈类摄入病例的11年回顾性分析,纳入标准与正在进行的开放标签水飞蓟宾试验相同:年龄>2岁、有采食野生蘑菇史、摄入后48小时内出现胃肠道症状、摄入后48小时内转氨酶高于正常上限。研究期间NPDS共报告8953例蘑菇暴露,296例符合纳入标准,经毒物控制中心确认和排除后最终纳入148例。总病死率为8.8%(13/148);水飞蓟宾/水飞蓟素治疗组病死率为9.5%(4/42),未治疗组为8.5%(9/106)。真菌学家鉴定出蘑菇的病例占16.9%(25/148),其中80%(20/25)含环肽;在这些确诊病例中,治疗组和未治疗组的病死率均为10%(1/10)。作者认为,这一当代病死率(8.8%)可能反映了急性肝损伤支持治疗的改善,应作为美国历史对照的当前标准。

要点

  • 美国NPDS 2008-2018年疑似含环肽蕈类摄入并符合纳入标准者总病死率为8.8%(13/148),远低于常被引用的>20%未治疗病死率。
  • 水飞蓟宾/水飞蓟素治疗组病死率为9.5%(4/42),未治疗组为8.5%(9/106),两组数值接近。
  • 真菌学家鉴定出蘑菇的病例占16.9%(25/148),其中80%(20/25)含环肽;确诊病例中治疗组和未治疗组病死率均为10%(1/10)。
  • 作者认为8.8%的病死率可能反映了急性肝损伤支持治疗的改善,应作为美国历史对照的当前标准。

适用人群与场景

  • 年龄>2岁、有采食野生蘑菇史、摄入后48小时内出现胃肠道症状、摄入后48小时内转氨酶高于正常上限的疑似含环肽蕈类摄入患者,数据来自美国国家毒物数据系统(NPDS)2008年1月1日至2018年12月31日报告病例。

诊断标准与关键阈值

  • 纳入标准与正在进行的开放标签水飞蓟宾试验相同:年龄>2岁;有采食野生蘑菇史;摄入后48小时内出现胃肠道症状;摄入后48小时内转氨酶高于正常上限。

研究设计与关键结果

  • 研究类型为11年(2008年1月1日至2018年12月31日)回顾性分析,数据来自美国国家毒物数据系统(NPDS),共报告8953例蘑菇暴露,296例符合纳入标准,经毒物控制中心确认和排除后最终纳入148例。
  • 总病死率为8.8%(13/148);水飞蓟宾/水飞蓟素治疗组病死率为9.5%(4/42),未治疗组为8.5%(9/106)。
  • 真菌学家鉴定出蘑菇的病例占16.9%(25/148),其中80%(20/25)含环肽;在这些确诊病例中,水飞蓟宾/水飞蓟素治疗组和未治疗组的病死率均为10%(1/10)。
  • 毒物控制中心调查应答率为60%(28/47),个体病例应答率为59%(174/296),随后排除26例,最终纳入148例。

证据类型、等级与局限

  • 证据类型为回顾性分析;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,疑似环肽蕈类中毒的当代病死率仅为8.8%,这可能反映了急性肝损伤支持治疗的改善,应作为美国历史对照的当前标准。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: This study was designed to determine the fatality rate of suspected cyclopeptide-containing mushroom ingestions reported to the National Poison Data System (NPDS).

BACKGROUND: Although silibinin reportedly improves survival in suspected cyclopeptide-containing mushroom ingestions, the greater than 20% untreated fatality rate that is often cited is based on decades-old data. An ongoing open-label silibinin trial will likely use historical cases as comparators. A recent single poison control center (PCC) study showed a fatality rate of 8.3%. This study was designed to validate those findings in the NPDS.

METHODS: This study was an 11-year (1/1/2008-12/31/2018) retrospective review of suspected cyclopeptide-containing mushroom ingestions reported to NPDS. Inclusion and exclusion criteria were the same as the ongoing silibinin trial: Age >2-years-old; history of eating foraged mushrooms; gastrointestinal symptoms within 48 h of mushroom ingestion; and aminotransferases above the upper limit of normal within 48 h after ingestion. Each original participating PCC confirmed eligibility, diagnosis, treatment, and outcome on included cases.

RESULTS: During the study period, 8,953 mushroom exposures were reported to NPDS, of which 296 met inclusion criteria. The PCC survey response rate was 60% (28/47 PCCs), and the individual case response rate was 59% (174/296). Twenty-six cases were subsequently excluded leaving 148 included cases. The overall mortality rate was 8.8% (13/148). Mortality in silibinin/silymarin-treated vs untreated cases was 9.5% (4/42), vs 8.5% (9/106), respectively. A mycologist identified mushrooms in 16.9% of cases (25/148), of which 80% (20/25) were cyclopeptide-containing. Among these confirmed cases, the mortality rate was 10% (1/10) in both silibinin/silymarin-treated and untreated cases.

CONCLUSIONS: The contemporary mortality rate of patients with presumed cyclopeptide-mushroom poisoning is only 8.8%. This likely represents improved supportive care for patients with acute liver injury and should be considered the current standard for historical controls in the United States.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. De Olano J, Wang JJ, Villeneuve E, et al. Current fatality rate of suspected cyclopeptide mushroom poisoning in the United States. Clin Toxicol (Phila). 2020. PMID: 32237919. doi:10.1080/15563650.2020.1747624

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。